0001104659-22-037426.txt : 20220324 0001104659-22-037426.hdr.sgml : 20220324 20220324134330 ACCESSION NUMBER: 0001104659-22-037426 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220324 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220324 DATE AS OF CHANGE: 20220324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FENNEC PHARMACEUTICALS INC. CENTRAL INDEX KEY: 0001211583 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32295 FILM NUMBER: 22765917 BUSINESS ADDRESS: STREET 1: PO BOX 13628 STREET 2: 68 TW ALEXANDER DRIVE CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: (919) 636-4530 MAIL ADDRESS: STREET 1: PO BOX 13628 STREET 2: 68 TW ALEXANDER DRIVE CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 FORMER COMPANY: FORMER CONFORMED NAME: FENNEC PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20140903 FORMER COMPANY: FORMER CONFORMED NAME: ADHEREX TECHNOLOGIES INC DATE OF NAME CHANGE: 20021223 8-K 1 tm2210369_8k.htm FORM 8-K
0001211583 false Nasdaq 0001211583 2022-03-24 2022-03-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 24, 2022

 

FENNEC PHARMACEUTICALS INC.

 

(Exact name of registrant as specified in its charter)

 

001-32295

(Commission File Number)

 

British Columbia, Canada   20-0442384

(State or other jurisdiction of

incorporation)

   (I.R.S. Employer Identification No.)

 

 

PO Box 13628, 68 TW Alexander Drive,

Research Triangle Park, NC

  

 

27709

(Address of principal executive offices)   (Zip Code)

  

Registrant’s telephone number, including area code: (919) 636-4530

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading symbol(s) Name of each exchange on which
registered
Common shares, no par value FENC Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01. Other Events.

 

On March 24, 2022, Fennec Pharmaceuticals Inc. issued a news release announcing it has completed its resubmission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARKTM (sodium thiosulfate anhydrous injection) for intravenous use. A copy of the news release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.

  

 

Item 9.01 Financial Statements and Exhibits.

 

  (d) Exhibits.

 

Exhibit No. Description
   
Exhibit 99.1 Press Release dated March 24, 2022

Exhibit 104 Cover Page Interactive Data File (embedded as Inline XBRL document)

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    FENNEC PHARMACEUTICALS INC.
     
     
Date March 24, 2022 By: /s/ Robert Andrade
   

Robert Andrade

Chief Financial Officer

 

 

 

 EX-99.1 2 tm2210369d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

FennecPharma

 

FENNEC PHARMACEUTICALS RESUBMITS NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINSTRATION FOR PEDMARKTM

 

 

Research Triangle Park, NC, March 24, 2022 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients one month to <18 years of age with localized, non-metastatic, solid tumors.

 

“We appreciate the FDA’s comments during the resubmission process and look forward to working closing with the Agency during the NDA review,” said Rosty Raykov, chief executive officer of Fennec Pharmaceuticals. “We are pleased to have reached this important step and Fennec remains committed to making PEDMARKTM available to reduce the risk of cisplatin induced ototoxicity in pediatric patients.”

 

About PEDMARK™

 

Cisplatin and other platinum compounds are essential chemotherapeutic agents for many pediatric malignancies.  Unfortunately, platinum-based therapies cause ototoxicity, or hearing loss, which is permanent, irreversible and particularly harmful to the survivors of pediatric cancer.

 

In the U.S. and Europe, it is estimated that, annually, over 10,000 children may receive platinum-based chemotherapy.  The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants and young children that suffer ototoxicity at critical stages of development lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement.

 

PEDMARK has been studied by cooperative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma.  SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

 

The Marketing Authorization Application (MAA) for sodium thiosulfate (tradename PEDMARQSI) is currently under evaluation by the European Medicines Agency (EMA).  PEDMARK has received Breakthrough Therapy and Fast Track Designation by the FDA in March 2018.

 

About Fennec Pharmaceuticals

 

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity in pediatric patients.   Further, PEDMARK has received Orphan Drug Designation in the U.S. for this potential use. Fennec has a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including the prevention of ototoxicity induced by platinum chemotherapy, in humans.  For more information, please visit www.fennecpharma.com

 

 

 

 

Forward Looking Statements

 

Except for historical information described in this press release, all other statements are forward-looking. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include the Company’s expectations regarding its interactions and communications with the FDA, including the Company’s expectations and goals respecting the resolution the issues raised in the CRL and the Company’s plans to address them, and the anticipated timing of the Company’s finalization and filing of an NDA resubmission for PEDMARK.  Forward-looking statements are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks and uncertainties relating to the Company’s reliance on third party manufacturing, the risk that unforeseen factors may delay the resubmission of the NDA, the risks of delays in or failure to obtain FDA approval of PEDMARK, the risks relating to the Company’s and its manufacturer’s ability to adequately address the concerns identified in the CRL, the risk that the resubmission of the NDA to the FDA will not be satisfactory, that regulatory and guideline developments may change, scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2021.  Fennec disclaims any obligation to update these forward-looking statements except as required by law.

 

For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.

 

For further information, please contact:

 

Investors:

Robert Andrade

Chief Financial Officer

Fennec Pharmaceuticals Inc.

(919) 246-5299

 

Media:

Elixir Health Public Relations

Lindsay Rocco

(862) 596-1304

lrocco@elixirhealthpr.com

 

 

 

 

 

 GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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fencf-20220324.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 fencf-20220324_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 fencf-20220324_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover
Mar. 24, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 24, 2022
Entity File Number 001-32295
Entity Registrant Name FENNEC PHARMACEUTICALS INC.
Entity Central Index Key 0001211583
Entity Tax Identification Number 20-0442384
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One PO Box 13628
Entity Address, Address Line Two 68 TW Alexander Drive
Entity Address, City or Town Research Triangle Park
Entity Address, State or Province NC
Entity Address, Postal Zip Code 27709
City Area Code 919
Local Phone Number 636-4530
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common shares, no par value
Trading Symbol FENC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 tm2210369_8k_htm.xml IDEA: XBRL DOCUMENT 0001211583 2022-03-24 2022-03-24 iso4217:USD shares iso4217:USD shares 0001211583 false NASDAQ 8-K 2022-03-24 FENNEC PHARMACEUTICALS INC. 001-32295 A1 20-0442384 PO Box 13628 68 TW Alexander Drive Research Triangle Park NC 27709 919 636-4530 false false false false Common shares, no par value FENC false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://adherex.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2210369_8k.htm fencf-20220324.xsd fencf-20220324_lab.xml fencf-20220324_pre.xml tm2210369d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2210369_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2210369_8k.htm" ] }, "labelLink": { "local": [ "fencf-20220324_lab.xml" ] }, "presentationLink": { "local": [ "fencf-20220324_pre.xml" ] }, "schema": { "local": [ "fencf-20220324.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "fencf", "nsuri": "http://adherex.com/20220324", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2210369_8k.htm", "contextRef": "From2022-03-24to2022-03-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://adherex.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2210369_8k.htm", "contextRef": "From2022-03-24to2022-03-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://adherex.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 16 0001104659-22-037426-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-037426-xbrl.zip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end